584 related articles for article (PubMed ID: 26130692)
1. PABPN1 suppresses TDP-43 toxicity in ALS disease models.
Chou CC; Alexeeva OM; Yamada S; Pribadi A; Zhang Y; Mo B; Williams KR; Zarnescu DC; Rossoll W
Hum Mol Genet; 2015 Sep; 24(18):5154-73. PubMed ID: 26130692
[TBL] [Abstract][Full Text] [Related]
2. Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies.
Miguel L; Frébourg T; Campion D; Lecourtois M
Neurobiol Dis; 2011 Feb; 41(2):398-406. PubMed ID: 20951205
[TBL] [Abstract][Full Text] [Related]
3. RNA binding mediates neurotoxicity in the transgenic Drosophila model of TDP-43 proteinopathy.
Ihara R; Matsukawa K; Nagata Y; Kunugi H; Tsuji S; Chihara T; Kuranaga E; Miura M; Wakabayashi T; Hashimoto T; Iwatsubo T
Hum Mol Genet; 2013 Nov; 22(22):4474-84. PubMed ID: 23804749
[TBL] [Abstract][Full Text] [Related]
4. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response.
Wang P; Deng J; Dong J; Liu J; Bigio EH; Mesulam M; Wang T; Sun L; Wang L; Lee AY; McGee WA; Chen X; Fushimi K; Zhu L; Wu JY
PLoS Genet; 2019 May; 15(5):e1007947. PubMed ID: 31100073
[TBL] [Abstract][Full Text] [Related]
5. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.
Janssens J; Van Broeckhoven C
Hum Mol Genet; 2013 Oct; 22(R1):R77-87. PubMed ID: 23900071
[TBL] [Abstract][Full Text] [Related]
6. TDP-43 proteinopathy in ALS is triggered by loss of ASRGL1 and associated with HML-2 expression.
Garcia-Montojo M; Fathi S; Rastegar C; Simula ER; Doucet-O'Hare T; Cheng YHH; Abrams RPM; Pasternack N; Malik N; Bachani M; Disanza B; Maric D; Lee MH; Wang H; Santamaria U; Li W; Sampson K; Lorenzo JR; Sanchez IE; Mezghrani A; Li Y; Sechi LA; Pineda S; Heiman M; Kellis M; Steiner J; Nath A
Nat Commun; 2024 May; 15(1):4163. PubMed ID: 38755145
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.
Wood A; Gurfinkel Y; Polain N; Lamont W; Lyn Rea S
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946763
[TBL] [Abstract][Full Text] [Related]
8. Depletion of Ubiquilin induces an augmentation in soluble ubiquitinated Drosophila TDP-43 to drive neurotoxicity in the fly.
Jantrapirom S; Lo Piccolo L; Yoshida H; Yamaguchi M
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3038-3049. PubMed ID: 29936333
[TBL] [Abstract][Full Text] [Related]
9. Cell-to-cell transmission of C9orf72 poly-(Gly-Ala) triggers key features of ALS/FTD.
Khosravi B; LaClair KD; Riemenschneider H; Zhou Q; Frottin F; Mareljic N; Czuppa M; Farny D; Hartmann H; Michaelsen M; Arzberger T; Hartl FU; Hipp MS; Edbauer D
EMBO J; 2020 Apr; 39(8):e102811. PubMed ID: 32175624
[TBL] [Abstract][Full Text] [Related]
10. [Neuropathology of TDP-43 proteinopathy].
Akiyama H; Hasegawa M
Brain Nerve; 2013 Dec; 65(12):1477-89. PubMed ID: 24323933
[TBL] [Abstract][Full Text] [Related]
11. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLD-U are recapitulated in SH-SY5Y cells.
Nonaka T; Arai T; Buratti E; Baralle FE; Akiyama H; Hasegawa M
FEBS Lett; 2009 Jan; 583(2):394-400. PubMed ID: 19111550
[TBL] [Abstract][Full Text] [Related]
13. [The molecular mechanisms of intracellular TDP-43 aggregates].
Nonaka T; Arai T; Hasegawa M
Brain Nerve; 2009 Nov; 61(11):1292-300. PubMed ID: 19938686
[TBL] [Abstract][Full Text] [Related]
14. TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy.
Turner BJ; Bäumer D; Parkinson NJ; Scaber J; Ansorge O; Talbot K
BMC Neurosci; 2008 Oct; 9():104. PubMed ID: 18957104
[TBL] [Abstract][Full Text] [Related]
15. [TDP-43 proteinopathies: ALS and frontotemporal dementias].
Prudlo J
Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S25-7. PubMed ID: 19685386
[TBL] [Abstract][Full Text] [Related]
16. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets.
Scotter EL; Chen HJ; Shaw CE
Neurotherapeutics; 2015 Apr; 12(2):352-63. PubMed ID: 25652699
[TBL] [Abstract][Full Text] [Related]
17. Znf179 E3 ligase-mediated TDP-43 polyubiquitination is involved in TDP-43- ubiquitinated inclusions (UBI) (+)-related neurodegenerative pathology.
Lee YC; Huang WC; Lin JH; Kao TJ; Lin HC; Lee KH; Lin HC; Shen CJ; Chang WC; Huang CC
J Biomed Sci; 2018 Nov; 25(1):76. PubMed ID: 30404641
[TBL] [Abstract][Full Text] [Related]
18. Traumatic injury induces stress granule formation and enhances motor dysfunctions in ALS/FTD models.
Anderson EN; Gochenaur L; Singh A; Grant R; Patel K; Watkins S; Wu JY; Pandey UB
Hum Mol Genet; 2018 Apr; 27(8):1366-1381. PubMed ID: 29432563
[TBL] [Abstract][Full Text] [Related]
19. RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy.
Chen HJ; Topp SD; Hui HS; Zacco E; Katarya M; McLoughlin C; King A; Smith BN; Troakes C; Pastore A; Shaw CE
Brain; 2019 Dec; 142(12):3753-3770. PubMed ID: 31605140
[TBL] [Abstract][Full Text] [Related]
20. The chaperone HSPB8 reduces the accumulation of truncated TDP-43 species in cells and protects against TDP-43-mediated toxicity.
Crippa V; Cicardi ME; Ramesh N; Seguin SJ; Ganassi M; Bigi I; Diacci C; Zelotti E; Baratashvili M; Gregory JM; Dobson CM; Cereda C; Pandey UB; Poletti A; Carra S
Hum Mol Genet; 2016 Sep; 25(18):3908-3924. PubMed ID: 27466192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
